HER2/positive and HER2/low in inflammatory breast cancer recurrence.

Autor: Movchan OV; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Bagmut IY; Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine., Shipko AF; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Smolanka Senior II; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Sheremet MI; Department of Surgery No.1, Bukovinian State Medical University, Chernivtsi, Ukraine., Kolisnyk IL; Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine., Bagmut OV; Faculty of Computer Sciences, Karazin Kharkiv National University, Kharkiv, Ukraine., Lyashenko AO; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Loboda AD; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Ivankova OM; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Dosenko IV; National Cancer Institute, Ministry of Health, Kyiv, Ukraine., Lazaruk OV; Department of Pathology, Bukovinian State Medical University, Chernivtsi, Ukraine., Gyrla YV; Department of Surgery No.1, Bukovinian State Medical University, Chernivtsi, Ukraine., Bilookyi OV; Department of Surgery No.1, Bukovinian State Medical University, Chernivtsi, Ukraine.
Jazyk: angličtina
Zdroj: Journal of medicine and life [J Med Life] 2022 Dec; Vol. 15 (12), pp. 1573-1578.
DOI: 10.25122/jml-2022-0213
Abstrakt: This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus group had an OS of 76.9% compared with 77.0% in the group with the HRplus/HER2plus subtype and 74.4% in the HR-/HER2plus group. Moreover, recurrence-free survival was 19.1% for the HRplus/HER2- group, 21.3% for the HRplus/HERplus group, and 11.7% for the HR-/HER2plus group. In our study, patients with HER2-low IBC could acquire a perfect response with preliminary systemic therapy, without disease progression or with stable disease on target alone. Further examination is important to decide on the most effective treatment regimens, in addition to mixing chemotherapy with HER2-low-focused on agents.
Competing Interests: The authors declare no conflict of interest.
(©2022 JOURNAL of MEDICINE and LIFE.)
Databáze: MEDLINE
Externí odkaz: